Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel boosts knee cartilage repair in older adults

NCT ID NCT06249828

Disease control Sponsor: L&C Bio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding MegaCarti® to standard microfracture surgery improves knee cartilage repair in people aged 50-65 with knee cartilage injuries. 61 participants received either microfracture alone or microfracture plus MegaCarti®. The main goal was to see if MRI scans at 48 weeks showed better cartilage regrowth with the added treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 50 years to 65 years 2. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate in the clinical trial and sign the consent form 3. Subjects with localized full-thickness cartilage defects in the knee joint, International Cartilage Repair Society(ICRS) Grade III or IV 4. Subjects whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms 5. knee cartilage defect size :1.5cm\^2 to 10cm\^2 Exclusion Criteria: 1. Patients who have autoimmune diseases (Ex. Rheumatoid arthritis) 2. When screening, Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (However, arthroscopy for diagnostic purposes is possible. Additionally, it is possible if hightibial osteotomy (HTO) has been performed in advance or is scheduled) 3. When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 1 month 4. When screening, Patients who took oral steroid within 2 weeks 5. Patients who can't take MRI scan 6. BMI index : 30kg/m\^2 or over 7. Patients who have gout or gout history in the knee 8. Women who are pregnant or breast-feeding, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception. 9. Patients with risk factor for bleeding 10. Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis,knee are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fractures, Stress osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis,knee

Contacts and locations

Locations

  • Ajou University Medical Center

    Gyeonggi-do, 16499, South Korea

  • Catholic Kwandong University International St.Mary's Hospital

    Incheon, South Korea

  • Chung-Ang University Gwangmyeong Hospital

    Gyeonggi-do, 14353, South Korea

  • Konkuk University Medical Center

    Seoul, 05030, South Korea

  • Yonsei Sarang Hospital

    Seoul, 06702, South Korea

  • Yonsei University College of Medicine, Gangnam Severance Hospital

    Seoul, 06273, South Korea

  • Yonsei University Health System, Severance Hospital

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.